Thus, therapeutically enhancing GlcNAc modification in combination with anti-PD-1/PD-L1 or other ICIs offers a promising strategy to improve T-cell immunoreactivity and strengthen the anti-tumor immune response in BC. Here, CD274 is linked to breast cancer.